Three-Dimensional Conformal Radiotherapy Combined with Gemcitabine and Docetaxel in the Treatment of Advanced Bladder Cancer and Its Effects on Inflammatory Factors and Immune Function

Table 7

Comparison of survival rates between the two groups.

Groups		1-year survival rate	2-year survival rate
Combination group	21	16 (76.19%)	10 (47.62%)
GT group	21	10 (47.62%)	4 (19.05%)
		4.215	5.821
		0.013	0.009